



CyPath Lung

Identifying Information: Patient identifiers, sample collection and receipt dates, report date, CPT codes, physician information



Collection Date: 07/13/2024 Received Date: 07/16/2024 Report Date: 07/17/2024 05:40 ICD 10 Codes: CPT Codes: 0406U X 1 Facility: Pulmonary Client Office Client ID Number: CP00267 Ordering Physician: Pulmonologist, M.D. Copies To:

Results Interpretation: VERY UNLIKELY malignancy in the lung



Result: The patient's result is reported relative to others who have lung cancer on a scale of 0.0 (Very Unlikely) to 1.0 (Very Likely). In this sample report, the patient is Very Unlikely to have lung cancer.

0.01	0.25	0.5 0.75	1.0
Patient Sample Result Value is 0.	00	Sample Adequacy: Measuring the number of cells and alv macrophages confirms that the sputum sample is adequa	
Reference Range: ≥0.00 and <0.10 Very unlikely ≥0.10 and <0.50 Unlikely ≥0.50 and <0.90 Likely ≥0.90 and =1.00 Very likely	Reference Range for interpreting numerical result	Sample Adequate: YES Number of Alveolar Macrophages per 10,000: 12. Absolute Number of Cells for Analysis: 173006	
			K.

Signed By: Jim Humphreys, M.D.06/28/2024 05:40

Test Description and Disclaimer

CyPath[®] Lung Flow Cytometry disclaimer

Testing is performed on sputum processed into a single-cell suspension labeled with the fluorescent porphyrin TCPP that preferentially binds to cancer cells and cancer-related cells. Cells are also stained with fluorescently labeled antibodies that identify hematopoietic and epithelial cells within the sputum sample. A viability dye is used to eliminate dead cells. After the sputum sample is acquired through the flow cytometer and the sample data is acquired, software searches for the presence of pre-defined features that distinguish individuals at high risk who have a high likelihood of lung cancer from those who do not. This Flow Cytometric assay was developed, and its performance characteristics of Accuracy, Precision, Specificity, and Sensitivity, determined by Precision Pathology Laboratory Services. This assay detects cell types that are indicative of the presence of lung cancer. The analysis is based on the following features: (1) proportion of cells with high TCPP fluorescence intensity, (2) proportion of cells with intermediate fluorescence intensity caused by the viability dye, and (3) proportion of cells that is CD206 negative but positive for one or more of the following markers: CD66b (granulocytes), CD3 (T cells) and CD19 (B cells) and (4) patient age. Failure of individual assays may occur due to problems with specimen quality or technical issues. Negative findings do not rule out the presence of an abnormality and not all positive findings are indicative of an abnormality. All findings should be correlated with patients clinical history and imaging. Sample data was acquired on the Navios EX Flow Cytometer (Beckman Coulter, Indianapolis, IN.). This test has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is for diagnostic purposes. It should not be regarded as investigational or for research. Precision Pathology Services Laboratory is certified under the Clinical Laboratory Improvement Am

Precision Pathology Laboratory Services,

3300 Nacogdoches Rd., Suite 110, San Antonio, TX // CLIA # 45D1064267 / CAP # 7221111/

Medical Director: Dr. Roby P. Joyce. This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please contact Precision Pathology Laboratory Services.